Valsartan is used clinical for receptor antagonist of angiotensin AT1, has good effect to the different degree of hypertension patients who used other antihypertensive without efficacy , is a new generation of highly efficient antihypertensive .
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium.
Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.
Valsartan is an angiotensin II receptor antagonistwith particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure. In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI) .
Sinezimboni eziningi zekhwalithi ephezulu ngokubambisana okujulile, ezingakunikeza ngemikhiqizo yekhwalithi ephezulu namanani ancintisanayo. Futhi singanikeza izaphulelo zokuthenga ngobuningi.Futhi sibambisana nezinkampani eziningi ezichwepheshile zokudlulisa impahla, zingaletha imikhiqizo ngokuphepha nangokushelela ezandleni zakho. Isikhathi sokulethwa cishe yizinsuku ezi-3-20 ngemuva kokuqinisekiswa kwenkokhelo.
Into | Test Standard | Testing Result | |
Ukubukeka | Powder | Iyahambisana | |
Color | Impushana emhlophe | Iyahambisana | |
Particle Size | 100% pass 80 mesh | Iyahambisana | |
Oder | Characteristic | Iyahambisana | |
Taste | Characteristic | Iyahambisana | |
Ukulahlekelwa Ekumisweni | ≤5.0% | 2.20% | |
Residue on Ignition | ≤0.1% | 0.05% | |
Residual acetone | ≤0.1% | Iyahambisana | |
Residual Ethanol | ≤0.5% | Iyahambisana | |
Heave Mentals | ≤10ppm | Iyahambisana | |
Na | ≤0.1% | <0.1% | |
Pb | ≤3 ppm | Iyahambisana | |
Total Plate | <1000CFU/g | Iyahambisana | |
Yeast & Mold | <100 CFU /g | Iyahambisana | |
E. Coli | Okubi | Iyahambisana | |
I-Salmonella | Okubi | Iyahambisana | |
Conclusion: Conform with USP Standard |
1. Ingabe uyimboni noma inkampani yokuhweba?
Siyimboni ehlanganisa i-comnay kanye nezohwebo, sinikeza isevisi eyodwa-stop.OEM ingamukelwa.
2. Uyawahlinzeka ngamasampula? Ingabe imahhala noma ingeziwe?
Amasampula wamahhala.Imali yesampula yempahla idinga ukukhokhwa eceleni kwakho.
3. Ingabe unazo izitifiketi ezihlobene nokulawulwa kwekhwalithi?
Isitifiketi se-ISO 9001:2008 sokuqinisekisa ikhwalithi.
4. Yini okufanele ngiyinikeze ukuze ngithole ikhotheshini?
I-Pls isazise ngohlobo lomkhiqizo oludingayo, inani le-oda, ikheli kanye nezidingo ezithile. Ikhotheshini izokwenzelwa inkomba yakho ngokuhamba kwesikhathi.
5. Hlobo luni lwendlela yokukhokha olukhethayo? Hlobo luni lwamagama olwamukelwayo?
Imigomo Eyamukelwe Yokulethwa: FOB,CFR,CIF,EXW;
Imali Yokukhokha eyamukelwe:USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Ulimi olukhulunywayo:IsiNgisi.
Izigaba zemikhiqizo